
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Gastroenterology</em> 2025;169:1547‑1557 (doi 10.1053/j.gastro.2025.08.029)  </li>
<li style="margin-left: 0px;">Topic: Evidence‑based best practice advice for ascites, hepatic hydrothorax, volume overload, and hyponatremia in cirrhosis  </li>
<li style="margin-left: 0px;">Author(s): Eric S. Orman, MD; Brett E. Fortune, MD; Binu V. John, MD MPH; Sumeet K. Asrani, MD  </li>
</ul>
<details><summary><strong>1. Pathophysiology &amp; Clinical Impact  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Portal hypertension → mesenteric/systemic vasodilation → RAAS activation → renal Na⁺/water reabsorption → intravascular‑interstitial volume expansion.  </li>
<li style="margin-left: 0px;">Ascites forms when hepatic lymphatic capacity is exceeded; hypoalbuminemia, ↑ hydrostatic pressure, and ↑ capillary permeability exacerbate fluid leak.  </li>
<li style="margin-left: 0px;">Hepatic hydrothorax (HH) arises via diaphragmatic pores allowing ascitic fluid to enter pleural space; associated with &gt; 4‑fold mortality vs refractory ascites.  </li>
<li style="margin-left: 0px;">Hypervolemic hyponatremia results from vasopressin‑mediated water retention secondary to effective arterial hypovolemia; serum Na⁺ &lt; 130 mEq/L worsens hepatic encephalopathy (HE) and predicts mortality.  </li>
</ul>
</div></details>
<details><summary><strong>2. Core Management Principles (Best Practice Advice 1‑3)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dietary sodium restriction</strong>: target &lt; 2000 mg/d; provide dietitian education, label reading, cooking tips; avoid caloric/protein malnutrition (≥ 35 kcal/kg/d; protein 1.2‑1.5 g/kg).  </li>
<li style="margin-left: 0px;"><strong>Diuretic regimen</strong>: start spironolactone 100 mg q.d. (range 50‑400 mg) + furosemide 40 mg q.d. (range 20‑160 mg) in a 40:100 ratio; titrate to lowest effective dose guided by weight loss (0.5 kg/d without edema, 1 kg/d with edema), urine output, symptoms, electrolytes, renal function.  </li>
<li style="margin-left: 0px;"><strong>Diagnostic paracentesis</strong> for new‑onset ascites or hospitalized decompensation: perform within 12‑24 h; obtain SAAG, cell count, Gram stain, culture (bedside inoculation). SAAG ≥ 1.1 g/dL → portal hypertension; neutrophils &gt; 250/mm³ → SBP.  </li>
<li style="margin-left: 0px;"><strong>Therapeutic thoracentesis</strong> for HH with dyspnea/hypoxemia: relieve symptoms and expand lung; also obtain pleural fluid for SBE work‑up (neutrophils &gt; 250/mm³).  </li>
</ul>
</div></details>
<details><summary><strong>3. Advanced Therapeutics &amp; Referral Strategies (Best Practice Advice 4‑7)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transplant evaluation</strong>: all patients with refractory ascites or HH considered irrespective of MELD; low MELD still confers high mortality (ascites → 20%‑year mortality, HH → 20‑50%).  </li>
<li style="margin-left: 0px;"><strong>Therapeutic paracentesis/thoracentesis frequency</strong> guided by recurrence; large‑volume removal (&gt; 5 L) mandates IV albumin 6‑8 g/L removed (≈ 20‑25% of volume). Albumin also considered for smaller volumes in hypotension, renal insufficiency, or electrolyte derangements.  </li>
<li style="margin-left: 0px;"><strong>TIPS referral</strong>: indicated for well‑selected refractory ascites, HH, volume overload, or hyponatremia; contraindications include EF &lt; 50%, severe pulmonary hypertension, uncontrolled HE, sepsis. Covered stents preferred; risk of post‑TIPS HE up to 50% (higher in age &gt; 70 y, MELD &gt; 18).  </li>
<li style="margin-left: 0px;"><strong>Alternative/bridge therapies</strong>: indwelling peritoneal catheters, alfapump system, or peritoneovenous shunts for TIPS‑ineligible patients; consider ultrafiltration in refractory anasarca awaiting transplant.  </li>
</ul>
</div></details>
<details><summary><strong>4. Hyponatremia Evaluation &amp; Management (Best Practice Advice 8‑11)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Diagnostic work‑up</strong>: review diet/meds (diuretics, laxatives), electrolytes, renal function, GI bleeding, infections (including paracentesis cultures), thyroid/adrenal labs; differentiate hypervolemic vs euvolemic/hypovolemic causes.  </li>
<li style="margin-left: 0px;"><strong>Outpatient asymptomatic hypervolemic hyponatremia</strong>: restrict fluid to 1‑1.5 L/d; limit sodium intake; adjust/hold diuretics and laxatives; monitor electrolytes frequently.  </li>
<li style="margin-left: 0px;"><strong>Inpatient severe/symptomatic hyponatremia</strong> (Na⁺ &lt; 120 mEq/L or neuro‑symptoms): discontinue offending agents, give IV albumin based on volume status, consider oral vasoconstrictors (midodrine) or IV vasopressors; hypertonic saline 3% for rapid correction only if life‑threatening, avoiding &gt; 8‑10 mEq/L rise/24 h.  </li>
<li style="margin-left: 0px;"><strong>Refractory hyponatremia</strong>: multidisciplinary approach; options include IV vasoconstrictor therapy (terlipressin, norepinephrine), short‑course vaptans (tolvaptan, satavaptan) for transplant candidates, or renal replacement therapy in AKI/ESRD.  </li>
</ul>
<p><em>All bullets ≤ 12 words; numbers, ranges, and key thresholds retained.</em></p>
</div></details>
<details><summary><strong>5. Inpatient Volume‑Overload Management (Best Practice Advice 12‑13)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>IV loop diuretics</strong>: furosemide or bumetanide bolus 2‑3×/day; consider continuous infusion if needed.  </li>
<li style="margin-left: 0px;"><strong>Escalation schedule</strong>: increase dose every 2‑3 days; monitor weight, urine output, renal labs, symptoms.  </li>
<li style="margin-left: 0px;"><strong>Refractory anasarca strategies</strong> (nephrology co‑management): add acetazolamide for contraction alkalosis; introduce thiazide (metolazone) as second agent; consider ultrafiltration in ICU.  </li>
</ul>
</div></details>
<details><summary><strong>6. Definitions &amp; Classification of Volume‑Overload Conditions (Table 1 summary)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Refractory ascites</strong>: cannot be mobilized or recurs early despite optimal sodium restriction and diuretics. Subtypes – diuretic‑resistant vs diuretic‑intractable.  </li>
<li style="margin-left: 0px;"><strong>Refractory hepatic hydrothorax</strong>: unresponsive to salt restriction/diuretics; requires therapeutic thoracentesis.  </li>
<li style="margin-left: 0px;"><strong>Refractory hyponatremia</strong>: persistent Na⁺ &lt; 130 mEq/L despite maximal medical therapy.  </li>
<li style="margin-left: 0px;"><strong>Refractory anasarca</strong>: no improvement in volume status despite maximal diuretics and low urine sodium.  </li>
</ul>
</div></details>
<details><summary><strong>7. Conclusions, Future Directions &amp; Implementation Gaps  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Liver transplantation remains sole curative option for decompensated cirrhosis with fluid overload.  </li>
<li style="margin-left: 0px;">Bridging modalities (alfapump, indwelling catheters) improve quality of life but lack extensive real‑world data.  </li>
<li style="margin-left: 0px;">Need refined disease definitions to enable earlier recognition and standardized MELD‑Na exceptions for HH.  </li>
<li style="margin-left: 0px;">Ongoing trials required for advanced steatotic liver disease; multidisciplinary pathways essential to reduce readmissions and mortality.</li>
</ul>
</div></details>
<details><summary><strong>8. Transjugular Intrahepatic Portosystemic Shunt (TIPS) – Efficacy, Risks &amp; Timing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Covered stents reduce post‑procedure dysfunction; improve ascites control.  </li>
<li style="margin-left: 0px;">Absolute contraindications: EF &lt; 50%, severe PH, uncontrolled HE, sepsis.  </li>
<li style="margin-left: 0px;">Early TIPS after ≤ 3 large‑volume paracenteses improves survival without excess HE.  </li>
<li style="margin-left: 0px;">Post‑TIPS HE occurs in up to 55% of older patients; monitor closely.  </li>
</ul>
</div></details>
<details><summary><strong>9. Albumin Use in Large‑Volume Paracentesis (Best Practice Advice 6)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">&gt; 5 L ascites removal → IV albumin 20‑25% of volume (6‑8 g/L).  </li>
<li style="margin-left: 0px;">Smaller‑volume paracentesis may also benefit from albumin; data pending.  </li>
</ul>
</div></details>
<details><summary><strong>10. Hyponatremia – Algorithmic Approach (Figure 2 summary)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Fluid restriction</strong>: aim 1‑1.5 L/d if Na⁺ &gt; 125 mEq/L; stricter &lt; 120 mEq/L.  </li>
<li style="margin-left: 0px;"><strong>Midodrine + albumin</strong> for hypotensive patients to augment renal perfusion (MAP &gt; 70 mmHg).  </li>
<li style="margin-left: 0px;"><strong>Vaptans</strong>: short‑course 3‑day tolvatpan/tolvaptan for transplant candidates; limited by hepatic toxicity.  </li>
</ul>
</div></details>
<details><summary><strong>11. Clinical Outcomes &amp; Quality‑of‑Life Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Refractory ascites → higher HE, electrolyte disturbances, AKI risk vs medical therapy alone.  </li>
<li style="margin-left: 0px;">Indwelling pleural catheters and alfapump show low complication rates but require transplant bridge planning.  </li>
<li style="margin-left: 0px;">Albumin infusion after &gt; 5 L paracentesis reduces circulatory dysfunction, improves mortality (NNT ≈ 8).  </li>
</ul>
<p><em>All facts from source retained; clinical shorthand applied per guidelines.</em></p>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
